a Department of Urogynaecology , King's College Hospital , London , United Kingdom.
Expert Opin Biol Ther. 2018 Oct;18(10):1005-1013. doi: 10.1080/14712598.2018.1510486. Epub 2018 Sep 10.
Overactive bladder is a common condition that can have a negative impact on quality of life. Botulinum Toxin A is a third line treatment for overactive bladder following conservative measures and anticholinergic medication. At present, OnabotulinumtoxinA is the only preparation licensed for this indication. More recently, trials have been undertaken to compare the efficacy of this to AbobotulinumtoxinA. Areas covered: This article aims to provide an overview of AbobotulinumtoxinA, which is currently not yet licensed for overactive bladder or neurogenic detrusor overactivity. It will detail the pharmacokinetics and dynamics, assess the available clinical trial data and make comparisons with current clinical practice. A systematic literature search was completed, using ovid Medline and Embase, with the aim to review all data concerning the administration of AbobotulinumtoxinA for the treatment of overactive bladder. Expert opinion: Currently, there are a lack of data on the use of AbobotulinumtoxinA for overactive bladder or neurogenic detrusor overactivity. Current evidence concentrates on its use in neurogenic detrusor overactivity, and there are data to show it may be as efficacious as OnabotulinumtoxinA. However, there is a lack of homogenous data to compare the two products and therefore we are unable to recommend this currently.
膀胱过度活动症是一种常见病症，会对生活质量产生负面影响。肉毒杆菌毒素 A 是继保守治疗和抗胆碱能药物治疗后治疗膀胱过度活动症的三线治疗药物。目前，只有奥氮平毒素 A 制剂被批准用于该适应症。最近，已经进行了试验来比较这种药物与阿博肉毒毒素 A 的疗效。
本文旨在概述阿博肉毒毒素 A，目前尚未被批准用于治疗膀胱过度活动症或神经源性逼尿肌过度活动症。本文将详细介绍其药代动力学和动力学，评估现有的临床试验数据，并与当前的临床实践进行比较。我们进行了系统的文献检索，使用了 ovid Medline 和 Embase，旨在回顾所有关于阿博肉毒毒素 A 治疗膀胱过度活动症的给药数据。
目前，关于阿博肉毒毒素 A 治疗膀胱过度活动症或神经源性逼尿肌过度活动症的使用数据不足。现有证据集中在其用于神经源性逼尿肌过度活动症上，有数据表明它可能与奥氮平毒素 A 一样有效。然而，缺乏同质数据来比较这两种产品，因此我们目前无法推荐使用。
